The clinical impact of donor-specific antibodies on antibody-mediated rejection and long-term prognosis after heart transplantation

2019 ◽  
Vol 24 (3) ◽  
pp. 245-251 ◽  
Author(s):  
Jennifer A. Su ◽  
Lee Ann Baxter-Lowe ◽  
Paul F. Kantor ◽  
Jacqueline R. Szmuszkovicz ◽  
JonDavid Menteer
Keyword(s):  
Heart Transplantation ◽  
Clinical Impact ◽  
Specific Antibodies ◽  
Antibody Mediated Rejection ◽  
Donor Specific Antibodies ◽  
Long Term Prognosis

Effect of recipient gender and donor‐specific antibodies on antibody‐mediated rejection after heart transplantation

2018 ◽  
Vol 19 (4) ◽  
pp. 1160-1167 ◽  
Author(s):  
Lee S. Nguyen ◽  
Guillaume Coutance ◽  
Joe‐Elie Salem ◽  
Salima Ouldamar ◽  
Guillaume Lebreton ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Specific Antibodies ◽  
Antibody Mediated Rejection ◽  
Donor Specific Antibodies

scholarly journals Long-term survival of the transplanted kidney and the clinical relevance of donor-specific antibodies

2020 ◽  
Vol 3 (1) ◽  
pp. 17-22
Author(s):  
Eva Svobodova ◽  
Sarka Valhova ◽  
Ondrej Viklicky ◽  
Ilja Striz ◽  
Jelena Skibova ◽  
...  
Keyword(s):  
Graft Survival ◽  
Solid Phase ◽  
Kidney Graft ◽  
Term Survival ◽  
Specific Antibodies ◽  
Antibody Mediated Rejection ◽  
Number Of Patients ◽  
Single Antigen ◽  
Donor Specific Antibodies

The aim of our study was to evaluate the relevance of donor-specific antibodies (DSA) as defined by solid-phase single-antigen (SA) assays for predicting long-term graft survival after kidney transplantation. Sera from 132 kidney transplant recipients were retrospectively tested before, 3, 6 and 12 months after transplantation. The incidence of rejection and graft survival was followed up for 7 years. We found 29 episodes of acute cellular rejection (CR), 21 cases of antibody-mediated rejection (AMR) and 18 graft failures due to immunological reasons. Pre-transplant DSA and DSA three months after transplantation correlated with an increased rate of AMR and impaired graft function. After the fourth year, recipients with persistent DSA were at a higher risk of graft failure (p = 0.0317). Antibody specificity was prevailingly to HLA class I antigens (66.6% DSA, 75% non-DSA). During the first year after transplantation, the number of patients with non-DSA decreased (30.3% to 10.7%), while, due to de novo production of antibodies, the number of DSA positive patients remained constant. Conclusion: Detection of antibodies to HLA antigens using solid-phase assays, especially single-antigen bead technology before and three months after transplantation is predictive for increased incidence of antibody-mediated rejection and impaired long-term kidney graft survival.

The Impact of Complement-Binding Donor-Specific Antibodies on Adverse Events Long-Term after Heart Transplantation

2019 ◽  
Vol 38 (4) ◽  
pp. S144
Author(s):  
J.A. Kobashigawa ◽  
M. Kittleson ◽  
D.H. Chang ◽  
E. Kransdorf ◽  
R. Levine ◽  
...  
Keyword(s):  
Adverse Events ◽  
Heart Transplantation ◽  
Specific Antibodies ◽  
Donor Specific Antibodies ◽  
The Impact

scholarly journals Late and Chronic Antibody-Mediated Rejection: Main Barrier to Long Term Graft Survival

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Qiquan Sun ◽  
Yang Yang
Keyword(s):  
Graft Survival ◽  
Graft Loss ◽  
Limited Effect ◽  
Hla Antibodies ◽  
Specific Antibodies ◽  
Antibody Mediated Rejection ◽  
Donor Specific Antibodies ◽  
Main Barrier ◽  
Lines Of Evidence

Antibody-mediated rejection (AMR) is an important cause of graft loss after organ transplantation. It is caused by anti-donor-specific antibodies especially anti-HLA antibodies. C4d had been regarded as a diagnosis marker for AMR. Although most early AMR episodes can be successfully controlled or reversed, late and chronic AMR remains the leading cause of late graft loss. The strategies which work in early AMR have limited effect on late/chronic episodes. Here, we reviewed the lines of evidence that late/chronic AMR is the leading cause of late graft loss, characteristics of late AMR, and current strategies in managing late/chronic AMR. More effort should be put on the management of late/chronic AMR to make a better long term graft survival.

Sign in / Sign up

Export Citation Format

Share Document